Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Vivo Capital, LLC (CIK 1674712) reported $1.20B across 44 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: ERAS ($196.6M, 16.34%), PRAX ($109.2M, 9.08%), TERN ($70.4M, 5.85%), TRVI ($60.8M, 5.05%), DBVT ($55.7M, 4.63%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | $196.6M | 16.34% | 12.2M | Added |
| 2 | PRAX | Praxis Precision Medicines | $109.2M | 9.08% | 338,895 | Added |
| 3 | TERN | Terns Pharmaceuticals Inc | $70.4M | 5.85% | 1.3M | Trimmed |
| 4 | TRVI | Trevi Therapeutics Inc | $60.8M | 5.05% | 5.1M | Hold |
| 5 | DBVT | DBV Technologies SA | $55.7M | 4.63% | 2.7M | Added |
| 6 | CMPX | Compass Therapeutics Inc | $50.5M | 4.20% | 9.5M | Hold |
| 7 | TNGX | Tango Therapeutics Inc | $45.1M | 3.75% | 2.2M | Hold |
| 8 | SABS | SAB Biotherapeutics Inc | $43.7M | 3.64% | 11.4M | Hold |
| 9 | CRVS | Corvus Pharmaceuticals Holdings | $41.0M | 3.41% | 2.8M | Added |
| 10 | DRUG | Bright Minds Biosciences Inc | $40.7M | 3.38% | 557,172 | Added |
| 11 | SVA | Sinovac Biotech Ltd. | $38.2M | 3.17% | 5.9M | Hold |
| 12 | DNTH | Dianthus Therapeutics Inc | $29.7M | 2.47% | 353,998 | Hold |
| 13 | DYN | Dyne Therapeutics Inc | $28.2M | 2.35% | 1.6M | Trimmed |
| 14 | ABVX | Abivax SA - ADR | $26.7M | 2.22% | 239,539 | Trimmed |
| 15 | NERV | Minerva Neurosciences Inc | $26.0M | 2.17% | 4.3M | Hold |
| 16 | ACRS | Aclaris Therapeutics, Inc. | $25.0M | 2.08% | 6.7M | Trimmed |
| 17 | ORIC | Oric Pharmaceuticals Inc | $23.4M | 1.95% | 1.8M | Trimmed |
| 18 | ANRO | Alto Neuroscience Inc | $23.3M | 1.94% | 1.0M | Hold |
| 19 | SNSE | Sensei Biotherapeutics Inc | $22.8M | 1.89% | 722,020 | New |
| 20 | AVBP | Arrivent BioPharma Inc | $20.4M | 1.70% | 885,916 | New |
| 21 | LB Pharmaceuticals Inc | $19.7M | 1.64% | 800,000 | Hold | |
| 22 | Veradermics Inc | $18.9M | 1.57% | 300,000 | New | |
| 23 | CAMP | CAMP4 Therapeutics Inc | $18.7M | 1.56% | 4.2M | Hold |
| 24 | MLTX | Moonlake Immunotherapeutics | $18.6M | 1.55% | 1.0M | Hold |
| 25 | DSGN | Design Therapeutics Inc | $17.2M | 1.43% | 1.6M | Hold |
Source: SEC Form 13F filings · as of 2026-03-31